NGM Biopharmaceuticals (NGM) PT Raised to $30 at Cowen
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/13/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
NGM Biopharmaceuticals (NGM) to Resume Trading at 8:30 am
February 24, 2020 8:26 AM ESTNGM Biopharmaceuticals (NASDAQ: NGM) to Resume Trading at 8:30 am
... MoreNGM Biopharmaceuticals (NGM) Phase 2 Study of Aldafermin in NASH Patients Shows Statistically Significant Achievement of Composite Endpoint
February 24, 2020 8:09 AM ESTClinically meaningful response rates of 38% of patients treated with aldafermin having liver fibrosis improvement of 1 stage and 24% of patients achieving resolution of NASH at 24 weeks--
--22% of aldafermin-treated patients versus 0% placebo achieved composite endpoint of both fibrosis improvement and resolution of NASH, a statistically significant result--
--Data support aldafermins differentiation in the NASH development landscape as a potential potent monotherapy that rapidly improves and sustains liver health with a favorable tolerability profile--
--Company to host conference call and webcast today at 8:30 a.m. ET (5:30 a.m.... More
